Source comparison
How to Use Sermorelin for Growth Hormone Release Protocol: Dosing Comparison
Dosing variability in Sermorelin protocols is driven by individual pituitary responsiveness, baseline GH secretion capacity, and whether the peptide is used standalone or stacked with other secretagogues. The table below compares standard research dosing range
This comparison does not assign a generated winner or score.
- Dosing variability in Sermorelin protocols is driven by individual pituitary responsiveness, baseline GH secretion capacity, and whether the peptide is used standalone or stacked with other secretagogues. The table below compares standard research dosing ranges and their associated response profiles.
- Low-Dose Maintenance
- 100–200 mcg
- 5–7 times per week
- 1.5–2× baseline
- Long-term pituitary support, mild metabolic enhancement
- Minimal side effects, sustainable long-term, often used in anti-aging protocols
- Standard Research Dose
- 200–500 mcg
- 2–4× baseline
- Most clinical trials, general GH optimization studies
- Optimal balance between efficacy and tolerability, widely studied range
- High-Dose Amplification
- 500–1000 mcg
- 3–5 times per week
- 3–6× baseline
- Short-term metabolic challenges, body composition research
- Increased nausea and flushing, not recommended beyond 12-week cycles
- Stacked with GHRP-2 or GHRP-6
- 200–300 mcg Sermorelin + 100–200 mcg GHRP
- 5 times per week
- 4–8× baseline
- Synergistic GH release studies, maximized pulsatile secretion
- GHRP compounds amplify Sermorelin's effect but require more careful monitoring for blood glucose and cortisol impact